MEF2D — gene · CancerIndex

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MEF2D MEF2D Rearrangement1
(prognostic)	B Acute Lymphoblastic LeukemiaALIAS	Prognostic	B	Supports Poor Outcome	4	submitted	EID8624 MEF2D encodes myocyte enhancer factor 2D and is mapped to chromosome 1q21–22. It is expressed throughout B-cell differentiation and inactivation of Mef2c/d results in an arrest in B-lymphoid maturatio… (full text at CIViC) PMID 27824051 · Gu et al., 2016 · Open in CIViC	civic
MEF2D Fusion3
(diagnostic)	B-lymphoblastic Leukemia With MEF2D RearrangementUNRESOLVED	Diagnostic	B	Supports Positive	4	accepted	EID12178 This study gathered diagnostic and prognostic data from pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients stored in the Tokyo Children’s Cancer Study Group (TCCSG) biobank. Among the 328 …

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Center for Cancer Genomics (CCG) Cancers of Unknown Primary Project (CUPP) CCG-CUPP	Malignant Neoplasm of Unknown Primary

Literature

25 per page, newest first.

pubmedPublishedShowing 1–3 of 3 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.